Vir Biotechnology CEO Marianne De Backer at JPM20 (Jeff Rumans)
July 20, 2023 09:28 AM EDT
R&D

Vir’s GSK-al­lied flu pre­ven­tion an­ti­body fails PhII, sink­ing shares and late-stage hope

Kyle LaHucik

Senior Reporter

Vir Biotech­nol­o­gy’s in­fluen­za an­ti­body has failed a crit­i­cal Phase II clin­i­cal tri­al, which could spell bad news for its part­ner GSK, who has the op­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times